Best Peptides for Cardiovascular Research UK 2026: GH Axis, Cardioprotection and Vascular Biology

This article is for Research Use Only. All peptides described are research compounds not approved for human therapeutic cardiovascular use in the UK. This overview is for scientific and educational purposes only.

Introduction: Peptide Research and Cardiovascular Biology

Cardiovascular disease (CVD) — encompassing coronary artery disease, heart failure, hypertension, stroke, and peripheral vascular disease — remains the leading cause of mortality globally. Despite decades of pharmacological advances, fundamental questions about cardiac repair, vascular regeneration, myocardial protection, and age-related cardiovascular decline remain incompletely answered. Research peptides offer mechanistically distinct tools for probing these questions, operating through growth hormone axes, angiogenic cascades, anti-fibrotic pathways, and anti-inflammatory circuits.

This research overview surveys the peptide compounds most actively studied in cardiovascular biology contexts, organising them by primary mechanism and target tissue. All compounds described are research-use-only; none carry therapeutic cardiovascular indications in the UK. Researchers selecting peptides for cardiovascular biology work should use this framework to identify compounds whose mechanisms align with specific research questions.

GH Axis Peptides: Cardiac Anabolic and Vasculoprotective Research

The somatotropic axis — GH, GHRH, and IGF-1 — is perhaps the best-characterised peptide system in cardiovascular research. Cardiomyocytes, endothelial cells, vascular smooth muscle cells, and cardiac fibroblasts all express GH receptors (GHR) and IGF-1 receptors (IGF-1R), making this axis a multi-target cardiovascular research system. Key GH axis peptides in cardiovascular research include:

Sermorelin (GHRH 1-29): The native bioactive fragment of GHRH. In preclinical cardiovascular models, sermorelin stimulates pituitary GH release and downstream IGF-1 production, driving cardiomyocyte survival (PI3K–Akt pathway), improving ejection fraction in GH-deficient animal hearts, and reducing myocardial fibrosis in cardiac remodelling models. Direct GHRH-R expression in cardiac tissue also mediates pituitary-independent cardioprotective effects in ischaemia-reperfusion models, including reduced infarct size and attenuated apoptotic signalling.

CJC-1295 (modified GHRH 1-29 with DAC): A longer-acting GHRH analogue with DAC (Drug Affinity Complex) technology extending plasma half-life. In cardiovascular research, CJC-1295 provides more sustained GH axis elevation, allowing study of chronic GH axis restoration effects on cardiac morphology, vascular endothelial function, and lipid metabolism. Its extended action profile makes it suitable for chronic cardiovascular research protocols studying somatopause-associated cardiovascular phenotype reversal.

Ipamorelin: A selective GH secretagogue (GHS) acting at ghrelin receptors (GHS-R1a) on pituitary somatotrophs. Ipamorelin’s cardiovascular research relevance derives from its selective GH release (with minimal cortisol, prolactin, or aldosterone stimulation) and downstream IGF-1 effects on cardiac and vascular tissue. Its clean pharmacological profile makes it useful for cardiovascular research where confounding endocrine effects need to be minimised.

GHRP-6: A GH secretagogue peptide with strong appetite-stimulating (ghrelin-mimetic) properties. Beyond GH secretagogue activity, GHRP-6 has been demonstrated to exert direct cardioprotective effects through a GH-independent, anti-apoptotic mechanism involving CD36 upregulation and downstream survival kinase activation. Research using GHRP-6 in I/R injury models consistently demonstrates reduced infarct size — a finding that has driven investigation of its cardiac-specific protective mechanisms independent of the pituitary axis.

Hexarelin: Structurally related to GHRP-6 with high GHS-R1a affinity and additional binding to cardiac CD36. Hexarelin is perhaps the most studied GH secretagogue in cardiovascular research: direct binding to CD36 on cardiomyocytes and macrophages produces GH-independent cardioprotection, anti-fibrotic effects, and LDL oxidation suppression through a unique non-pituitary mechanism. Hexarelin studies in dilated cardiomyopathy, I/R injury, and ventricular hypertrophy models are foundational to understanding GHS-R1a cardiovascular biology.

Tissue Repair Peptides: Cardiac and Vascular Regeneration Research

TB-500 (Thymosin Beta-4): The most studied endogenous cardiac regeneration peptide. TB-500’s primary cardiovascular research relevance is its promotion of cardiomyocyte survival after ischaemic injury, epicardial progenitor cell activation, and endothelial cell migration in angiogenesis. The peptide activates the PI3K–Akt–eNOS pathway in endothelial cells, promoting nitric oxide production and vascular repair. In MI (myocardial infarction) models in rodents and larger animals, Tβ4 administration reduces infarct size, preserves ejection fraction, and promotes angiogenic neovascularisation of ischaemic zones. TB-500 also modulates cardiac fibroblast-to-myofibroblast transition, potentially limiting pathological cardiac fibrosis post-MI.

BPC-157: A 15-amino acid synthetic peptide derived from human gastric juice protein. While best characterised for gastrointestinal and tendon healing research, BPC-157 has significant cardiovascular research relevance through its potent angiogenic effects — stimulating VEGF production, endothelial tube formation, and NO-mediated vasodilation. In preclinical cardiovascular models, BPC-157 promotes collateral vessel formation in ischaemic hindlimb and cardiac territory models, and protects against aortic lesion formation. Its NO-eNOS pathway activation makes it an interesting research tool for studying peptide-mediated endothelial biology.

Metabolic Peptides with Cardiovascular Research Relevance

Tirzepatide (dual GIP/GLP-1 receptor agonist): Research in the SURPASS and SURMOUNT trials demonstrates that tirzepatide produces substantial weight reduction, glycaemic improvement, and — critically for cardiovascular research — significant reduction in major adverse cardiovascular events (MACE) in the SURPASS-CVOT data. Mechanistically, GLP-1 receptor activation produces direct cardiac effects including cardioprotection through cAMP-PKA signalling, reduced cardiac inflammation, and ischaemic preconditioning-like effects. Tirzepatide’s additional GIP receptor agonism may further contribute to cardiac and vascular biology through complementary cAMP-mediated pathways. It represents one of the most clinically validated peptide systems in cardiovascular outcomes research.

Retatrutide (triple GIP/GLP-1/glucagon receptor agonist): The most potent obesity research compound currently in development, with cardiovascular outcomes trial data accumulating. Glucagon receptor activation adds thermogenic effects and direct cardiac effects (positive chronotropy and inotrophy in acute settings) to the GLP-1/GIP cardiovascular biology. Phase 2 retatrutide data demonstrates substantial metabolic improvement with a cardiovascular risk factor profile suggesting MACE reduction potential, currently under formal evaluation in Phase 3 CVOT design.

Tesamorelin: Approved for HIV-associated lipodystrophy, tesamorelin is a GHRH analogue that reduces visceral adipose tissue (VAT) — an independent cardiovascular risk factor. Its cardiovascular research relevance extends to its effects on lipid profiles (reducing triglycerides, LDL-C) and IGF-1 restoration in HIV-positive individuals, where metabolic CVD risk is substantially elevated. Research using tesamorelin in MASH (metabolic dysfunction-associated steatohepatitis) models also implicates the compound in hepatic lipid biology with secondary cardiovascular risk implications.

AOD-9604: The C-terminal GH fragment (hGH 176-191) that stimulates lipolysis through β3-adrenergic receptor-independent pathways. Visceral fat reduction — AOD-9604’s primary documented research effect — is mechanistically linked to cardiovascular risk reduction through adipokine normalisation (leptin/adiponectin ratio), reduced ectopic lipid deposition (hepatic and cardiac), and reduction in the pro-inflammatory adipose tissue secretome that promotes endothelial dysfunction and atherosclerosis.

Longevity Peptides and Cardiovascular Ageing Research

Epitalon: A tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal cortex that activates telomerase (TERT) and may slow telomere attrition. Cardiovascular relevance: telomere shortening in endothelial cells and cardiomyocytes is increasingly recognised as a mechanistic contributor to endothelial senescence, vascular ageing, and age-related cardiac dysfunction. Research models using epitalon to study telomere dynamics in cardiovascular cells provide a framework for investigating whether telomere-targeted approaches can delay vascular ageing phenotypes.

MOTS-C: A mitochondrial-derived peptide encoded in the 12S rRNA region of mtDNA. Its cardiovascular research relevance stems from its AMPK activation in skeletal muscle and cardiac tissue, PGC-1α-driven mitochondrial biogenesis, and insulin-sensitising effects. Cardiac mitochondrial dysfunction is a central mechanism in heart failure pathophysiology, making MOTS-C an interesting tool for studying mitochondrial biology in cardiac energy metabolism research. MOTS-C serum levels decline with age in parallel with age-related metabolic and cardiovascular risk increases.

GHK-Cu (Copper tripeptide): A plasma-derived copper-binding tripeptide with established research activity in wound healing, anti-inflammatory, and collagen remodelling contexts. Its cardiovascular research relevance includes endothelial protection (Nrf2 activation reducing oxidative stress), anti-fibrotic properties in cardiac and vascular smooth muscle contexts, and potential modulation of atherogenic plaque biology through its antioxidant and metal chelation properties.

Angiogenesis and Vascular Biology Research Peptides

IGF-1 LR3: The long Arg3 variant of IGF-1 with enhanced receptor binding and resistance to IGFBP inhibition. In vascular biology research, IGF-1R signalling in endothelial cells promotes eNOS phosphorylation, NO production, VEGF expression, and angiogenic tube formation. IGF-1 LR3 is used in research to study these endothelial pathways at doses that achieve sustained receptor engagement. The compound’s known proliferative effects require careful research design in cardiovascular contexts to distinguish angiogenic (beneficial) from proliferative (potentially atherogenic smooth muscle) effects.

MGF (Mechano Growth Factor): The IGF-1 splice variant produced in response to mechanical stress, expressed in both skeletal and cardiac muscle. In the heart, MGF is upregulated following mechanical overload and myocardial ischaemia, potentially functioning as a local cardiomyocyte survival and repair signal. Research into MGF’s cardiac biology — particularly its E-peptide domain’s cell migration and anti-apoptotic effects — provides mechanistic insight into how the heart responds to stress and injury at the IGF-1 system level.

Research Peptide Selection Framework for Cardiovascular Studies

Selecting the most appropriate peptide for cardiovascular research requires alignment between the specific cardiovascular question and the peptide’s primary mechanism. A broad framework:

• Cardiac ischaemia/reperfusion biology: GHRP-6, Hexarelin, BPC-157, TB-500 — all have documented infarct size reduction activity in I/R models
• Cardiac fibrosis and remodelling: TB-500, BPC-157, Sermorelin/CJC-1295 (via IGF-1) — all modulate TGF-β/myofibroblast biology at different pathway levels
• Endothelial function and angiogenesis: BPC-157, TB-500, IGF-1 LR3, GHK-Cu — all promote NO biology and/or VEGF-mediated angiogenesis
• Metabolic cardiovascular risk: Tirzepatide, Retatrutide, Tesamorelin, AOD-9604, MOTS-C — all address adiposity, insulin resistance, or lipid metabolism as upstream CVD drivers
• Cardiovascular ageing and somatopause: Sermorelin, CJC-1295, Ipamorelin — restore GH/IGF-1 axis for studying somatopause-CVD links in aged animal models
• Cardiac mitochondrial biology: MOTS-C, Epitalon — mitochondrial and telomere biology in cardiac ageing models

Regulatory and Safety Research Framing

All cardiovascular research utilising the peptides described in this overview is conducted under appropriate UK research governance frameworks including institutional ethics committee approval and, where animal work is involved, Home Office project licences under the Animals (Scientific Procedures) Act 1986. None of the peptides described carry therapeutic cardiovascular indications in the UK; all are supplied under MHRA research-use exemptions for non-clinical research purposes. No cardiovascular treatment protocols, clinical recommendations, or cardiac dosing guidance are derived from this overview.